Categories
Finance News

RISE OF ANTIBODY DRUG CONJUGATES WITH THE RECENT APPROVALS | Roots Analysis

Antibody drug conjugates (ADCs) have captured the attention of both large and small pharmaceutical companies, and academic / research institutions, for more than a decade. For the past few years, several failures of clinical trials were blamed for the lack of interest of some companies in this therapeutic approach. However, after a decade-long dribble of antibody drug conjugates, FDA has approved three new drugs in 2019.

Recently, in April 2020, the FDA approved another ADC, named TRODELVY™ by Immunomedics for the treatment of patients suffering with metastatic triple-negative breast cancer, who have received at least two prior therapies for patients with relapsed or refractory metastatic disease. As per the recent updates, around 90 ADCs are being evaluated under more than 600 clinical trials. Further, it is believable from the fact that, an increase in the recent FDA approvals portends a comeback for antibody drug conjugates.

For more information please click on the following link:

Antibody Drug Conjugates Market

The recent FDA approvals brought the total number of marketed ADCs to nine. These include, ADCETRIS® (2011, Seattle Genetics / Takeda Oncology), KADCYLA® (2013, Roche / Genentech), BESPONSA® (2017, Pfizer), MYLOTARG™ (2017, Pfizer), LUMOXITI® (2018, AstraZeneca / MedImmune), POLIVY™ (2019, Roche / Chugai Pharmaceuticals), PADCEV™ (2019, Astellas / Seattle Genetics), ENHERTU® (2019, AstraZeneca and Daiichi Sankyo) and TRODELVY™ (2020, Immunomedics).

SIGNIFICANT CAPITAL INVESTMENT IN THIS DOMAIN

Over the years, monetary assistance from angel investors, venture capitalists and funding schemes of various public and private organizations / funds, along with assistance from regulatory authorities, have allowed start-ups / small companies to further their R&D efforts related to the ADC therapeutics. According to our research, more than 80% of the total investment (in terms of the amount invested) was made in last five years alone; a total amount of nearly USD 4 billion has been invested since 2015.

In terms of grants, Tulane university and Scripps Research were awarded the maximum amount, which account for USD 3.2 million, each. Additionally, Children’s Hospital of Philadelphia was awarded approximately USD 3.1 million.

RESEARCH & DEVELOPMENT AGREEMENTS ARE THE MOST PROMINENT IN THIS AREA

Several companies active in the ADCs domain have entered into partnerships with other stakeholders in the last decade to provide better technologies and develop efficient products. Our findings depicted that, research and development agreements (40%) were the most popular type of agreement, which were inked between the companies present in this domain. This is followed by product / technology licensing agreements, which accounted of 35% of the total collaborations. Further, we observed that, majority of the collaborations were inked by the stakeholders which were headquartered in North America.

WHICH TYPE OF STRATEGIES ARE BEING ADOPTED BY THE COMPANIES FOR THE COMMERCIALIZATION OF THEIR ADC PRODUCTS?

In order to understand the commercialization strategies being adopted by companies focused on development of ADCs, we considered the marketed drugs that were approved during the period 2011-2019 (till August). We observed that the stakeholders involved in this domain were found to adopt several different strategies to promote the drug, before and after the regulatory approval.

LIKELY ADOPTION OF ANTIBODY DRUG CONJUGATES BY 2030

By 2030, the major contribution to the market is expected to be made by North America (56%), followed by EU5 (29%). However, in terms of target indication, major proportion (more than 55%) of the total market (USD 15.2 billion), is likely to be held by ADC therapeutics developed for the treatment of therapeutic areas, such as breast cancer (28%), urothelial cancer (10%), DLBCL (9%) and Hodgkin’s lymphoma (9%).

In terms of type of linker, more than 65% of the share, the market is likely to be dominated by the ADCs using the linkers, namely VC (32%), SMCC (21%) and Hydrazone linker (15%).

A detailed information on the key players, recent developments, number of grants awarded, number of patents filed, key opinion leaders in this domain and the likely market evolution, was done by Roots Analysis in H2 2019. For Further, information visit this link.

For more information please click on the following link:

Antibody Drug Conjugates Market

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Finance News

Outsourcing has become a popular trend in ophthalmic drug development domai | Roots Analysis

 

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of innovator companies have demonstrated a preference to outsource certain aspects of ophthalmic drug development and production operations to contract service providers.

To get a detailed information on the key players, recent developments, manufacturing capacity available in this domain and the likely market evolution, visit this link

Outsourcing has become a popular trend in ophthalmic drug development industry

Over 240 companies claim to offer manufacturing services for a wide range of ophthalmic APIs and drug FDFs, at varying scales of operation

Since 2000, more than 75 new ophthalmology focused CMOs have been established. Amidst the tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry. This has caused many service providers to actively expand their respective service portfolios, either through strategic acquisitions or facility / capability expansions.

The market landscape is currently dominated by the presence of large firms (having more than 500 employees), which represent close to 60% of the total number of industry stakeholders. In addition, at present, close to 70% players claim to offer FDF manufacturing services for ophthalmic drugs. It is worth noting that nearly 80% contract FDF manufacturers formulate ophthalmic drug products in the form of liquid / suspension. Of these, more than 150 companies offer primary packaging services in glass / plastic bottles, specifically for products that are available in the form of eye drops. However, packaging of ophthalmic drug FDF in ampoules / vials is likely to gain significant momentum in the near future, owing to the growing demand for sterile injectables.

In order to acquire competencies across the supply chain and cater to evolving needs of sponsors, companies have established presence across different regions, having been certified by various regulatory authorities

Globalization, increased support from local governments and relatively low labor costs have driven innovator companies, even located in developed regions, to favor outsourcing opportunities within Asia-Pacific (primarily in India, China, Japan, Bangladesh and South Korea).

Most of the installed, global ophthalmic drug manufacturing capacity belongs to established CMOs, accounting for over 80% of available capacity across various geographies

The global, installed ophthalmic FDF manufacturing capacity of companies providing contract services is estimated to be more than 65 kiloliters. It is worth mentioning that companies in Asia-Pacific and Europe currently account for approximately 54% and 21% of the global installed FDF manufacturing capacity (in terms of volume), respectively.

On the other hand, the global, installed ophthalmic API manufacturing capacity of companies providing contract services, is estimated to be around 1,980 kiloliters (in terms of volume). It is worth mentioning that the available capacity is primarily driven by players operating at both clinical and commercial scale, which are known to possess 75% of the total installed capacity.

It is worth highlighting that very large companies contribute around 45% of the overall capacity for both ophthalmic APIs and FDFs. However, small sized companies contribute only 8% of the overall capacity for both domains. It is worth mentioning that the available capacity is primarily driven by players operating at both clinical and commercial scale, which are known to possess 75% of the total installed capacity.

To get a detailed information on the key players, recent developments, manufacturing capacity available in this domain and the likely market evolution, visit this link

Outsourcing has become a popular trend in ophthalmic drug development industry

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Finance News

Next Generation Immune Checkpoint Inhibitors and Stimulators: Another Big Opportunity | Roots Analysis

There is an urgent unmet need for developing innovative and effective cancer therapeutics for the treatment of patients with late-stage and refractory cancer. Amidst the widespread initiatives to develop more targeted anti-cancer therapies, immune checkpoint inhibitors emerged as a highly specific and potent option to eradicate tumor cells with minimal side effects.

Once the body recognizes an entity as foreign, it is capable of mounting an immune response against it that ultimately results in the selective elimination of the foreign entity. Moreover, the immune system retains a memory of the event and has the capability to keep it from relapsing. Immuno-oncology involves the study of the above phenomenon in order to develop novel treatment options that leverage innate potential of the immune system to treat disease in a specific manner and prevent it from recurring. Immunotherapies have been shown to stimulate the immune system by three different mechanisms, blocking immune inhibitory signals, activating immunostimulatory pathways and stimulating components of the innate and adaptive immune systems to elicit a disease-specific immune response.

Next Generation Immune Checkpoint Inhibitors and Stimulators

The Potential of Immuno-modulators:

The success of first-generation immune checkpoint inhibitors has opened a new arena for researchers and pharmaceutical companies in this domain. Several alternative stimulatory and inhibitory pathways, other than those targeting CTLA-4, PD-L and PD-L1, are being investigated across various stages of preclinical and clinical development. Therapies targeting these alternative checkpoint proteins, such as TIM-3, LAG-3, GITR, OX40, CD47 and CD38, have been termed as next generation immune checkpoint modulators. Next generation immune modulators are the beneficiaries of this change and are certain to pave the way for effective treatment of several forms of cancer. A number of preclinical and clinical studies have established the potential of immune checkpoint modulators, both as monotherapies and combination therapies. Further, other intriguing combinations are emerging with immunotherapies and other established therapeutic modalities, such as radiotherapy and chemotherapy. With both, big and small players, investing large amount of resources to investigate the anticancer potential of immune checkpoint modulators, these therapeutic modalities are expected to become mainstream in the foreseen future.

The Evolving Landscape of Next Generation Immune Checkpoint Inhibitors and Stimulators

Over the years, significant strides have been made in immune checkpoint modulation research, revealing several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are now being exploited for development of next generation immune checkpoint-based therapies.

Moreover, clinical studies of combinatorial immune checkpoint blockade / co-stimulation, involving the newly identified checkpoints and known immune checkpoint inhibitor therapies, have demonstrated the potential to further augment therapeutic benefits. It is worth highlighting that these molecules have also shown to be capable of regulating immune tolerance and preventing / treating autoimmune disorders. Therefore, backed by promising clinical results and expanding applicability of therapies being investigated in late stages of development, the immune checkpoint inhibitors and stimulators market is poised to witness substantial growth in the foreseen future.

Next generation immune checkpoint therapy developers have invested extensively in conducting clinical studies to evaluate the therapeutic potential of these therapies and translate into commercial success stories.

The number and the geographical distribution of clinical trials are two important indicators that determine the therapeutic viability and the future potential of innovative pharmacological interventions. Moreover, the geographical distribution directly indicates the various markets that are actually open to receiving / adopting the novel intervention(s) under investigation. Further, as more product candidates are approved by regulatory authorities across the globe, the number of clinical trials across different regions is anticipated to increase. To get a detailed information on the key players, recent developments, and the likely market evolution, visit this link

Next Generation Immune Checkpoint Inhibitors and Stimulators

Other Recent Offerings

  1. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  2. Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market, 2019-2030
  3. Antibody Drug Conjugates Market (5th Edition), 2019-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Finance News

Needle-free Injection System: A light bearer in the fight against the thick darkness of COVID-19 | Roots Analysis

The apocalyptic images of the COVID-19 induced locked-down world are heart wrenching. All healthcare related domains are being created at a rapid rate. Around the world, the coronavirus pandemic is overstretching health services and reportedly more than 40 companies have boosted their R&D efforts to hit the bulls eye and deliver the much awaited vaccines to the mass.

But here comes the twist, developing vaccine is like solving one part of the big puzzle, followed by development comes the challenge of administering the vaccine. Drop the beat, and here comes the decades old pain saver technology a.k.a. needle-free injection system. The device that was initially used for administration of morphine, later underwent multiple improvements, which made its use more efficient, secure, and more dependable.

For more information please click on the following link:

Needle-free Injection System

So, what’s wrong with the conventional injection systems? The limitations are countless and highly bothering. Count some major hurdles as listed; health care workers are constantly at a risk of acquiring serious diseases due to needlestick injuries. According to the World Health report, more than 3 million occupation-related percutaneous injuries are reported annually, worldwide. Needles contaminated with bodily fluids of patients may accidently prick healthcare workers and contaminants / pathogens may get transferred. Such injuries may occur while drawing blood, administering intravenous drugs, disposing used needles, handling medical waste and performing numerous other routine procedures.

Needlestick injuries are known to be responsible for the transmission of a variety of blood-borne diseases, such as hepatitis B, hepatitis C, and Human Immunodeficiency Virus infection and Acquired Immune Deficiency Syndrome (HIV / AIDS). These are some of the well-known diseases but now one deadly virus adds to this existing list. Yes, you guessed it right, the world’s common nightmare, COVID-19. Imagine getting infected with the virus through any means while administering the vaccine. No, you don’t want to imagine, no one would. This needle-free injection system can be the blessings you can sought in hard time like this.

There are almost 40 developers in this domain, with 59% of them being in North America and 28% in Europe, while rest of them are based in the Asia-Pacific region. Nearly 70% of the devices that are marketed / being developed are designed for multiple administrations; these devices are primarily used for delivery of fixed dose of drug at regular intervals. Almost 35% of these devices are designed to administer vaccines, which is a huge advantage while looking from the lens of COVID-19.

Needle free injection technology harnesses the energy required to propel a preset dose of a given drug formulation, which is loaded in unique cassettes provided with the system. Upon administration, an ultrafine stream of fluid penetrates and delivers the formulation to the desired layer of the skin in a fraction of a second. The whole event of the injection process takes less than 0.5 second to complete and this time is really crucial if we imagine vaccinating millions with COVID-19 vaccines.

For more information please click on the following link:

Needle-free Injection System

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Finance News

Microbiome-based Live Biotherapeutics Contract Manufacturing: Rising Opportunities for Specialized CMOs / CDMOs | Roots Analysis

What is the current development pipeline of microbiome-based live biotherapeutics?

With over 85 products under preclinical and clinical development, the current development pipeline of microbiome-based live biotherapeutics has several promising candidates, which are anticipated to get commercialized over the next few years. Hence, the demand for R&D and manufacturing services for such products is anticipated to increase beyond the capabilities of innovator companies alone.

To get a detailed information on the key players, recent developments, manufacturing capacity available in this domain and the likely market evolution, visit this link

Microbiome-based Live Biotherapeutics Contract Manufacturing

Who are the most likely partners (microbiome-based live biotherapeutic drug developers) for microbiome contract manufacturers?

Majority of the drug developers are based in of 29 drug developers based in North America, followed by players based in Europe and Asia-Pacific. Further, with more than 70% of the pipeline in preclinical / discovery stage, a significant surge in outsourcing activity is anticipated in the mid to long term, driving the growth in the contract manufacturing space.

Can we measure the clinical demand?

Yes, we believe over 17,000 patients are already enrolled in clinical trials worldwide. By 2030, over 31,000 patients are estimated to be enrolled in the clinical trials involving the use of microbiome-based live biotherapeutics. Industry players are anticipated to contribute majority (over 60%) of the demand in the short-term as well as long-term. North America and Europe are the hubs with over 65% of the patient registrations.

What are the key trends shaping up the market?

Manufacturing is presently one of the biggest bottlenecks in this domain; manufacturing such products is both technically challenging and financially demanding. It is not easy to find contract manufacturers with sufficient capacity and capabilities to support the manufacturing of different types of bacterial strains. In addition, there is a need for additional manufacturing facilities to accommodate microbial production operations to cater to the growing demands of sponsor companies.

What are the recent expansions / developments in this market?

One of the leading CDMO in this domain, Arranta Bio, has undertaken a number of initiatives in the last few months. Recently in May, Arranta Bio announced the completion of its process development laboratory expansion project with the addition of early-clinical GMP capacity at its Center of Excellence for Microbiome Process Development. In November, last year, the company acquired microbiome process development and clinical contract manufacturer, Captozyme. Earlier, in April 2019, Lonza and Chr. Hansen have entered into a strategic agreement to establish a joint venture company (now named BacThera) for the manufacturing of live biotherapeutic products, with an investment of EUR 90 million. The company plans to expand its capabilities to commercial scale manufacturing soon in 2020.

To get detailed insights about this market, check out the report here

Microbiome-based Live Biotherapeutics Contract Manufacturing

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Finance News

Growing Pipeline of Microbiome-based Live Biotherapeutics Fuels the Manufacturing Demand | Roots Analysis

Live biotherapeutics are fragile bacteria, which require ideal conditions of heat, moisture and pH of products, to survive and prevent premature germination. In fact, manufacturing is presently one of the biggest bottlenecks in this domain; manufacturing such products is both technically challenging and financially demanding. One of the biggest challenges in the development of a probiotic product is related to its stability. It is very difficult to maintain the number of live bacteria during product formulation and storage. It is not easy to find contract manufacturers with sufficient capacity and capabilities to support the manufacturing of different types of bacterial strains.

Need for outsourcing microbiome-based live biotherapeutics manufacturing operations

In fact, the current development pipeline of microbiome-based live biotherapeutics has several promising candidates, which are anticipated to get commercialized over the next few years. Hence, the demand for R&D and manufacturing services for such products is anticipated to increase beyond the capabilities of innovator companies alone.  

Service Providers Offering Live Biotherapeutics Manufacturing

Over 55 contract manufacturers and in-house players are engaged in the manufacturing of microbiome-based live biotherapeutics, a new class of therapeutics which uses bacteria as drugs. The majority of these CDMOs have the expertise for anaerobic fermentation of microbial strains, which require strict environmental conditions.

Microbiome CMOs – list of companies

List of microbiome-based live biotherapeutics manufacturers

To know about the companies (CMOs / CDMOs / In-house players) that are engaged in the manufacturing of microbiome-based live biotherapeutics, check out our report Live Biotherapeutics

 

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Finance News

Growing Oligonucleotide-based Drugs Pipeline Escalates Manufacturing Demand | Roots Analysis

As therapeutic agents, oligonucleotides are known to be associated with several unique features, such as high selectivity and potency (similar to biologics), and differentiated pharmacology, which further augment their drug-like properties. At present, eight oligonucleotide-based drugs are available in the market, namely (in reverse chronological order of year of approval) GIVLAARI™ (2019), ONPATTRO® (2018), TEGSEDI™ (2018), SPINRAZA® (2016), EXONDYS 51® (2016), DEFITELIO® (2016), KYNAMRO™ (2013), and MACUGEN® (2004). As the market for such therapeutic interventions continues to evolve, it is likely to induce a steadily growing demand for oligonucleotides.

Recent Clinical Activity in the Oligonucleotide Domain

More than 200 unique oligonucleotide-based product candidates are currently being evaluated in various preclinical / clinical phases of development. In fact, we came across more than 270 registered clinical trials focused on oligonucleotides, till 2019; it is worth noting that the maximum (34) number of trials were registered in 2019.

Further, these trials recruited more than 47,400 patients, across the globe. It is important to highlight that most of the trials being conducted within this domain are / were evaluating antisense oligonucleotides (110), followed by those involving the use of siRNAs (101).

Current Annual Demand for Oligonucleotide Manufacturing

By 2030, it is expected that siRNAs are likely to capture the highest share of the overall clinical demand for oligo nucleotides. In addition, in 2030, majority of the clinical demand is likely to be generated by oligonucleotides being investigated for the treatment of oncological disorders, followed by those intended for ophthalmic disorders and metabolic disorders. Further, majority of the current as well as future demand for oligonucleotides is likely to generated in developed regions, such as North America and Europe.

Recent Activity in the Oligonucleotide Domain

The current oligonucleotide manufacturing landscape comprises of more than 80 players that claim to have the capability to manufacture oligonucleotides, at varying scales, for various pharmacological interventions. Further, in order to keep pace with the growing demand for oligonucleotides, these service providers are increasingly investing in or entering into collaborations to expand their existing capabilities. Majority of the partnership instances were reported to be manufacturing and supply agreements, followed by mergers / acquisitions.

Oligonucleotides – recent expansions

To know more about the evolving oligonucleotide manufacturing market, check out the report Under –

Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030

 

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Finance News

Favorable Demand Dynamics within the Ophthalmic Drugs Contract Manufacturing Market | Roots Analysis

In the past two decades, advances in optometry, along with an increased understanding of human eye and vision care, have led scientists to develop innovative treatment methods in order to treat eye disorders and to overcome the limitations offered by conventional medical practices. The current ophthalmic diseases treatment landscape is characterized by a number of blockbuster small molecule-based therapies, namely ALPHAGAN®, COSOPT®, LUMIGAN®, PAZEO®, RESTASIS®, TRAVATAN Z®, and XALATAN®, and a robust pipeline of over 400 candidate drugs in various stages of clinical development, designed for the treatment of approximately 1,000 chronic eye disorders. This has led to increasing demand for ophthalmic drugs’ contract manufacturing

Next Generation Immune Checkpoint Inhibitors and Stimulators

Clinical trials focused on ophthalmic drugs

Over the years, stakeholders engaged in the development and manufacturing of ophthalmology drugs have invested significant capital towards assessing the clinical viability of their proprietary product candidates. During our research, we came across more than 10,700 registered clinical trials focused on ophthalmic drugs till Q3 2019; the maximum number of trials were registered in 2018. North America (53%) and Europe (26%) were observed to be the current hubs of clinical research activity related to this field. The abovementioned studies were conducted on a total of more than 4.5 million patients, recruited across different trial sites across the world. Of these, over 1.9 million were recruited in the Asia-Pacific regions.

Likely Evolution of Supply Chain and Demand of Ophthalmic Drugs

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of innovator companies have demonstrated a preference to outsource certain aspects of ophthalmic drug development and production operations to contract service providers.

The current, annual manufacturing demand for commercialized ophthalmic drug FDFs is projected to grow at an annualized rate of 11.9%, till 2030. According to our estimates, close to 40% of the anticipated future demand is likely to be for ampoules / vials packaging, followed by glass / plastic bottles (28%). Further, a significant proportion of the FDF demand is likely to come from ophthalmic drugs commercialized for age-related macular degeneration.

It is worth highlighting that Asia-Pacific is likely to continue to lead (in terms of manufacturing demand) among other geographies. Within this region, the global commercial demand for ophthalmic FDF is estimated to grow at a CAGR of 12.7%, in the time period 2020-2030.

Several CMOs engaged in this domain, are expanding their businesses to offer end-to-end services to clients, thereby, operating as one-stop-shops. This business model is known to offer a number of advantages to both service providers and sponsors. In addition to cost benefits, it also helps minimize multiple technology transfers and thereby, expedites time to market for clients’ products. For a CMO, having a wider service portfolio, is known to increase business opportunity and guarantee long term relations with sponsor companies.

To get a detailed information on this emerging domain, visit this link

Ophthalmic Drugs Contract Manufacturing Market

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Finance News

CRISPR Can be a Solution to Address the COVID-19 Pandemic | Roots Analysis

As we know, COVID-19 is causing large scale loss of life and severe human suffering. With the pandemic spreading across the globe, researchers are racing against the clock to develop diagnostic tools, vaccines and treatments. Recently, WHO has launched a Solidarity clinical trial to assess relative effectiveness of four potential drugs against COVID-19. Further, there are close to 40 clinical trials of vaccines are ongoing, however, as per experts, it may take more than a year to develop a vaccine.

In order to enhance COVID-19 drug discovery and develop rapid testing kits, various academic institutes, non-profit institutes, scientific pioneers and biopharmaceutical companies have also been leveraging benefits of CRISPR technology.

For more Insights Click under –

CRISPR Can be a Solution to Address the COVID-19 Pandemic

The CRISPR / Cas9 system has revolutionized the field of genetic engineering. It enables researchers to alter the genomes of a range of organisms with relative ease.  Currently, it has emerged as a promising tool that is used extensively for editing genomes and for the development of novel treatment options. CRISPR is popularly known as search engine for biology, as it has emerged as a location finder, rather than site specific cleavage tool. The figure below highlights the key potential areas and benefits of CRISPR in order to fight against novel coronavirus.

Rapid and Economical Diagnostic Tests

Presently, COVID-19 testing capacity is limited by a number of factors, such as requirements for complex procedures, need for laboratory instrumentation, and dependence on limited supplies. Therefore, there is an urgent need for rapid detection kits. CRISPR has been explored by scientists for diagnosis of infectious diseases. The underlying mechanism involves binding of guide RNA with a protein of Cas family which cuts the target and shreds the nearby RNA or DNA. When CRISPR hits a target, the reporter molecule releases a fluorescent signal. This is further analysed by paper tests dipped into a patient sample, such as blood, urine, or saliva, which further shows up as a line on the testing strip. Researchers have been utilizing CRISPR-based tools and technologies to detect RNA of virus in patient samples. Sherlock Biosciences has already made history, as it received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its Sherlock™ CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19. The kit is designed for use in laboratories and can provide results within an hour. The company claims that more than 1 million tests can be performed within a week.

Enhancing Drug Discovery

CRISPR technology aids in the study of interaction of virus with human cells. This enables the generation of appropriate cell models for faster discovery of new potential treatment options, or identification of an existing drug combination that may provide a treatment solution. For instance, researchers are exploring molecular mechanisms of the novel virus by utilizing CRISPR technology, which can ultimately assist in identifying potential drug combinations.

CRISPR-based COVID-19 Therapy

Researchers at Stanford University have been working on the development of a gene targeting anti-viral agent against COVID-19, using PAC-MAN technology. The technology has been modified to be used against the deadly virus. It consists of a virus-killing enzyme, such as Cas13 and a guide RNA, which commands Cas13 to destroy specific nucleotide sequences in the coronavirus’s genome. Based on several studies, it has been revealed that PAC-MAN has the ability to neutralize the coronavirus and stop it from replicating inside cells. Based on information available, work is currently ongoing, and researchers are finding a solution to deliver this technology to lung cells. Multiple delivery methods are currently under evaluation.

A lot of companies are currently active in providing CRISPR-based genome engineering services. To get a detailed information on the key players, recent developments, and the likely market evolution.

For more Insights Click under –

CRISPR Can be a Solution to Address the COVID-19 Pandemic

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Finance News

ASCO 2020: AstraZeneca Presents a Game-Changer in Lung Cancer | Roots Analysis

While the ASCO 2020 presentation was virtual this year, the phase III results from AstraZeneca’s drug Tagrisso, in lung cancer patients, were as real as they could get. 89% of patients treated with Tagrisso were alive and cancer-free after two years, compared to 53% of patients treated with the placebo.

For more Insights Click under –

https://www.rootsanalysis.com/reports/targeted-drug-delivery.html

Tagrisso: A Game Changer in Lung Cancer

CRISPR technology aids in the study of interaction of virus with human cells. This enables the generation of appropriate cell models for faster discovery of new potential treatment options, or identification of an existing drug combination that may provide a treatment solution. For instance, researchers are exploring molecular mechanisms of the novel virus by utilizing CRISPR technology, which can ultimately assist in identifying potential drug combinations.

CRISPR-based COVID-19 Therapy

The results highlighted by AstraZeneca were impressive for several reasons. Some of the key takeaways are highlighted below:

  1. Adjuvant osimertinib is the first targeted agent in a global trial to show a statistically significant and clinically meaningful improvement in DFS patients with stage IB / II / IIIA EFGRm NSCLC.
  2. Overall, there was a 79% reduction in the risk of disease recurrence or death with osimertinib.
  3. Osimertinib vs placebo DFS rates at 2 years were 89% vs 53%, respectively.
  4. A consistent improvement in DFS was seen regardless of whether patients received prior adjuvant chemotherapy.
  5. The safety profile was consistent with the established safety profile of osimertinib.

In fact, the treatment was so effective that the study was un-blinded two years early, on the recommendation of an impartial monitoring board. The figure below highlights the results presented by AstraZeneca.

Will this lead to new market opportunities in lung cancer?

Around 60,000 additional patients may be eligible for treatment if the drug is approved in early-stage, post-surgical lung cancer. Patients would take the drug for two to three years.

According to Bloomberg, the study results’ strength suggests that most doctors will adopt the therapy now as the standard of care for this new set of patients, rather than waiting for additional data on overall survival.

For more Insights Click under –

https://www.rootsanalysis.com/reports/targeted-drug-delivery.html

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]